An in vivo model for the experimental selection of drugs able to prevent immune complex glomerulonephritis.

Abstract

Polyclonal activation of lymphocytes and immune complex-mediated glomerular lesions were induced in C57Bl/6 mice by injecting bacterial lipopolysaccharide (LPS) twice a week for 2 weeks. The usefulness of such a model for in vivo evaluation of immunomodulatory and therapeutic effects of drugs, was investigated by treating mice with DIAM4, a cyclophosphazenic compound known to modulate polyclonal activation of lymphocytes and to prevent mouse lupus nephritis. Prevention of LPS-triggered lymphocyte polyclonal activation and glomerular lesions was observed in the DIAM4-treated mice. Such a model can be used conveniently to select compounds effective in the treatment of immune glomerulonephritis.

• Authors: S In, A D Le Lann, F Oksman, E L Fournié, J F Labarre, H Benoist, G J Fournié
• Journal: International journal of immunopharmacology (Int J Immunopharmacol) Vol. 14 Issue 5 Pg. 871-6 (Jul 1992) ISSN: 0192-0561 [Print] England
• PMID: 1387391 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antibodies, Antinuclear
• Aziridines
• Complement C3
• Lipopolysaccharides
• Organophosphorus Compounds
• DIAM 4

Topics

• Animals
• Antibodies, Antinuclear (analysis)
• Aziridines (therapeutic use)
• Complement C3 (metabolism)
• Disease Models, Animal
• Female
• Glomerulonephritis (immunology, prevention & control)
• Immune Complex Diseases (immunology, prevention & control)
• Lipopolysaccharides (toxicity)
• Mice
• Mice, Inbred C57BL
• Organophosphorus Compounds (therapeutic use)